AndhraNews.net
Home » Business News » 2014 » August » August 25, 2014

Alchemia Appoints Jenni Pilcher as Chief Financial Officer


August 25, 2014 - Brisbane, Australia

Alchemia Limited (ASX: ACL), a drug discovery and development company, announced today the appointment of Ms. Jenni Pilcher as its Chief Financial Officer (CFO). Ms. Pilcher brings extensive financial leadership experience to Alchemia. She is currently the CFO of Mesoblast, where she has been part of the executive team for the past seven years, and she also serves as Company Secretary. Jenni's appointment is effective on September 1, 2014.

As a member of Mesoblast's executive team during a period of rapid growth for the company, Jenni built the finance group and partnered with the CEO to successfully execute four capital raises totaling more than $230m with Australian, US and UK investors. She was also a key executive in the successful completion of several transactions including a major out-licensing transaction, a company acquisition, a product acquisition, and a contract manufacturing partnership. In 2012, Jenni added the role of Company Secretary to her CFO responsibilities.

"After an extensive search, we are very pleased to add such a high caliber financial leader to our team," commented Thomas Liquard, Chief Executive Officer of Alchemia. "Jenni has an outstanding track record in the biotech industry and her executive maturity and experience will be of great benefit to Alchemia as we enter what is a critical phase in the company's development with the impending results of our pivotal trial for HA-Irinotecan in metastatic colorectal cancer (mCRC)."

"I am thrilled to join Alchemia at this exciting time and I look forward to applying my expertise and experience to help the Company capitalize on its future growth opportunities," said Jenni Pilcher. "I am excited to partner with Thomas, the Executive Management team and the Board to continue building on the company's past successes."

Prior to joining Mesoblast, Jenni spent six years with ASX 200 company Spotless Group, progressing through a variety of financial roles, and also worked within the finance teams at Cadbury Schweppes plc and international pharmaceutical group Medeva plc, both based in the United Kingdom. Jenni earned a Bachelor of Business Studies (BBS), is a Chartered Accountant (CA), and an associate of the Governance Institute of Australia (AGIA).

About Alchemia Limited
Alchemia is a drug discovery and development company marketing FDA approved fondaparinux, an injectible antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The Company is also developing a late stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Lead asset HA-Irinotecan is in a pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in two Phase II investigator-sponsored trials, one of which is in collaboration with Merck Serono combining HA-Irinotecan with Erbitux® (cetuximab).

Alchemia is also exploring additional small molecule drug discovery targets via an internal discovery platform VAST, based on the Company's deep chemistry expertise. The VAST technology is being developed in collaboration with leading academic institutions and is partnered with AstraZeneca AB.

Erbitux® is a trademark of Merck KGaA.

Contacts
www.alchemia.com.au

Alchemia Limited
Thomas Liquard
Chief Executive Officer
Alchemia Limited
Tel: +61 7 3340 0200

Investor Relations Australia
Rebecca Wilson or Gabriella Hold
Buchan Consulting
Tel: + 61 3 9866 4722
rwilson@buchanwe.com.au / ghold@buchanwe.com.au

Investor Relations USA
Candice Knoll
Blueprint Life Science Group
+1 415 375 3340 Ext. 105
cknoll@bplifescience.com

MarketWire

Comment on this story

Share